Pressmeddelande -

Medivir - Winner of Sweden BIO Award 2010

Medivir’s CEO Ron Long received the SwedenBIO Award 2010 from research and further education minister Tobias Krantz at life sciences industry organization SwedenBIO’s annual conference in Stockholm.

Medivir won the award for all the successes the company achieved in 2009. The citation for Medivir, worthy winner of the SwedenBIO Award 2010, reads as follows:

Citation

During the year, management positioned the company to evolve from a research and development enterprise into a pharmaceutical company with proprietary products and its own Nordic sales organization. Its new cold sore product Xerclear™ is the first, and so far only, pharmaceutical able to demonstrate in clinical trials that it can prevent the incidence of cold sores, a condition affecting 2 million people in Sweden alone. Medivir secured market approval on its two key markets of the US and Europe in 2009, with unique competitive advantages. At the same time, the company built its own sales organization, while also achieving substantial advances in international partnerships with other companies, particularly in the hepatitis C segment. Perseverance, partnership and a global perspective are the core ingredients of Medivir’s recipe for success.

 “2009 was a year Medivir made a lot of progress on the road to becoming an established pharmaceutical company. It’s really stimulating from me and my colleagues to receive the SwedenBIO Award with this citation,” commented Medivir’s CEO Ron Long.

 

Ämnen

  • Vetenskap, teknik

Kategorier

  • ron long
  • munsår
  • xerclear
  • hepatit c
  • swedenbio award 2010

Relaterad media

Relaterat innehåll

  • Daewoong to distribute Medivir’s Xerclear™ in South Korea

    Medivir AB today announced it has appointed Daewoong Pharmaceutical Co. Ltd. as its exclusive distributor for Xerclear™ in South Korea. Under the terms of the agreement, Daewoong will be responsible for obtaining the regulatory approvals, and for marketing, sales and distribution of Medivir’s cold sore product in the territory.

  • Medivir appoints Luxembourg Pharmaceuticals as distributor for Xerclear™ in Israel

    Medivir AB (OMX: MVIR), the research-based speciality pharmaceutical company focused on infectious diseases, is today pleased to announce the appointment of Luxembourg Pharmaceuticals Ltd, as the exclusive distributor for Xerclear™, Medivir’s marketed and innovative treatment for recurrent cold sores, in Israel and the Palestinian Authority.

  • Medivir receives USD 45 million from Meda for North American rights for Xerese™

    Huddinge, Sweden - Medivir AB (OMX: MVIR) today announced that it has renegotiated the terms of its commercial partnership with Meda (OMX: MEDA A) for Xerese™, its unique marketed product for cold sores (herpes labialis). Meda launched the product in the US in February 2011 and Medivir currently receives a mid-teens royalty on Meda’s sales in this market.

Fyll i din epostadress för att följa Medivir AB

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Medivir AB.

Okej